Savara Inc. (SVRA) Stock Price & Analysis
Savara Inc. (SVRA) closed at USD 4.95 on Thursday, October 29, 2026, down 1.39% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 5.02; the Oct 29, 2026 session ranged USD 4.92–5.13 on volume of 1,740,801 shares. Market capitalization is $1.02B, with a 52-week range of USD 3.86–7.01 (NMS). Source: Nexqual, retrieved October 29, 2026 at 21:53 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SVRA.md
Key facts (SVRA)
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $2.2M; 1 not under a Rule 10b5-1 plan ($2.2M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.67 on a 1–5 scale) (9 analysts), mean target USD 11.06 (range 9–16).
- Total return with dividends: 1Y +15.1% vs S&P 500 +14.4%; 5Y +326.7% vs S&P 500 +79.1%.
- Next earnings: 2026-11-11 (date not yet confirmed by the company), EPS estimate USD -0.17, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-11
- Dividend: SVRA paid no cash dividend in the last five years.
- Short interest: 16.35% of float (as of 2026-10-15), 11.9 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SVRA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$41.5M | -$38.8M | -$60.0M | -$103M | -$124M | -$144M |
| Net income | -$43.0M | -$38.1M | -$54.7M | -$95.9M | -$119M | -$139M |
| EPS (diluted) | -$0.32 | -$0.25 | -$0.33 | -$0.48 | -$0.53 | — |
| Free cash flow | -$40.1M | -$34.6M | -$51.4M | -$89.1M | -$101M | -$111M |
| Cash + short-term investments | $161M | $126M | $162M | $196M | $236M | — |
| Total debt | $25.7M | $26.1M | $26.3M | $26.6M | $29.9M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (SVRA)
P/B 7.1x · FCF yield -10.88% · Earnings yield -13.70% · Net cash $143M · EV $874M
Insider sales (SEC Form 4, open-market, last ~7 months) (SVRA)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-22 | Lowrance David L | Chief Financial Officer | 394,528 | $2.2M | 42.4% | No | Too little history (no open-market trades in 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (SVRA)
Consensus Buy (mean 1.67 on a 1–5 scale), 9 analysts; mean target USD 11.06 (low 9, high 16).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | JP Morgan | Initiated | Overweight | $12 |
Total return (dividends reinvested) (SVRA)
| 1Y (from 2025-10-30) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +15.1% | +326.7% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | +15.2% | +33.6% |
| Volatility (annualized) | 53.7% | 56.6% |
| Max drawdown | -39.2% (Dec 2025→Oct 2026) | -61.1% (Mar 2024→Jun 2025) |
Dividends (SVRA)
SVRA paid no cash dividend in the last five years.
Short interest (SVRA)
28,737,897 shares sold short, 16.35% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 43,343,616 shares (-33.7%). Days to cover: 11.9 (short shares ÷ average daily volume).
SVRA earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.16 | −$0.15 | Miss −6.7% | — |
| — | Quarter ended Dec 31, 2025 | −$0.13 | −$0.12 | Miss −8.3% | — |
| — | Quarter ended Sep 30, 2025 | −$0.14 | −$0.13 | Miss −7.7% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
SVRA recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Aug 11, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
SVRA suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | PARI Pharma | “For the supply of our exclusive, proprietary eFlow® nebulizer system that is part of the MOLBREEVI drug-device combination, we have a long-term supply agreement in place with PARI.” |
| Supplier | GEMA Biotech | “At that meeting, we gained alignment with FDA on the requirements necessary to show comparability between drug substance manufactured at GEMA and drug substance manufactured at Fujifilm and, subsequently, decided to resubmit the BLA with Fujifilm as the drug substance supplier.” |
| Supplier | Patheon UK | “We have entered into an agreement and related work orders with Patheon under which Patheon manufactures our MOLBREEVI product candidate for clinical trials.” |
| Partner | Selvita | “We entered into a master services agreement with Selvita on January 17, 2024 (the "Selvita MSA") under which Selvita performs batch control testing and analyses of our MOLBREEVI drug product and drug substance through certain cell-based bioassays.” |
| Partner | Evercore Inc. (EVR) | “On July 6, 2021, the Company entered into a Sales Agreement with Evercore Group L.L.C. ("Evercore"), as sales agent (the "ATM Agreement"), permitting the Company to offer and sell up to an aggregate of $100.0 million of shares of its common stock, par value $0.001 per share, from time to time through Evercore in "at the market offerings" as defined in Rule 415 under the Securities Act of 1933, as amended.” |
Quoted from the company's 10-K filed Mar 13, 2026.
SVRA company outlook (results filed Aug 6, 2020)
- “EX-99.1 2 d26703dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SAVARA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Announces Final Clinical Study Design for IMPALA 2, the Next Phase 3 Study of Molgradex in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Study Expected to Start in Q1 2021 AUSTIN, TX August 6, 2020 Savara Inc.”
- “At the end of the 48-week double-blind period, both treatment arms will rollover into a 48-week open-label follow-on period in which all patients will receive Molgradex 300 µg administered once-daily. The study is expected to start in the first quarter of 2021.”
- “One hundred and thirty-three patients were enrolled in the primary analysis population (younger patients between 6-21 years of age) out of a target of 150. Top line results from AVAIL are still expected in early 2021. 1 Molgradex for nontuberculous mycobacterial (NTM) lung infection In March 2020, the exploratory ENCORE study stopped enrolling new patients due to COVID-19 concerns.”
- “The Company anticipates an additional ~$46.0 million in gross proceeds from the second tranche of the December 2019 financing.”
Quoted word-for-word from the SEC 8-K results press release.
SVRA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.17 | $-0.15 | −$0.02 | $0 | 6 |
| Next quarter (ends Dec 2026) | $-0.17 | $-0.14 | −$0.03 | $1.8M | 6 |
| Current fiscal year (ends Dec 2026) | $-0.65 | $-0.58 | −$0.07 | $1.8M | 6 |
| Next fiscal year (ends Dec 2027) | $-0.37 | $-0.29 | −$0.07 | $79.6M | 6 |
SVRA options: expected move
Options price a move of about ±33.0% (±$1.63) by Nov 20, 2026, which includes earnings on Nov 11, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 22 | 180.8% | ±33.0% |
| Dec 18, 2026 | 50 | 279.5% | ±77.1% |
| Feb 19, 2027 | 113 | 118.7% | ±62.4% |
| May 21, 2027 | 204 | 202.0% | ±109.0% |
30-day implied volatility 166.4% vs 55.9% realized over the last 30 trading days. Put/call ratio (volume) 0.08. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 21:53 UTC)
| Price | USD 4.95 |
|---|---|
| Change | ▼ 1.39% (down) |
| Previous Close | USD 5.02 |
| Open | USD 5.05 |
| Day Range | USD 4.92 – 5.13 |
| 52-Week Range | USD 3.86 – 7.01 |
| Volume | 1,740,801 shares |
| Market Cap | $1.02B |
| Exchange | NMS |
Technical Analysis (SVRA)
Nexqual's technical model rates SVRA "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 29, 2026 at 21:53 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 52.17 (neutral) |
| vs SMA50 | Below (USD 5.09) |
| MACD | -0.09 (negative) |
Analyst Ratings (SVRA)
Wall Street analysts rate SVRA "Buy" based on 9 analysts, with a mean price target of USD 11.06 (range USD 9–16), per Nexqual as of October 29, 2026 at 21:53 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 11.06 |
| High Target | USD 16 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (SVRA)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD -0.17 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.16 vs est -0.15 ▼ miss |
| 2025-12-31 | USD -0.13 vs est -0.12 ▼ miss |
| 2025-09-30 | USD -0.14 vs est -0.13 ▼ miss |
Source: Nexqual, October 29, 2026 at 21:53 UTC.
Financials & Fundamentals (SVRA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -105.48% |
| Debt / Equity | 0.21 |
| Current Ratio | 10.13 |
| Total Cash | $174.82M |
| Total Debt | $30.41M |
Source: Nexqual, October 29, 2026 at 21:53 UTC.
Financial Health Score (SVRA)
Nexqual rates Savara Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 21:53 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $173M cash and investments vs $30M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — Operating cash flow -$101M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -97%, ROA -72.5% (last 4 quarters, SEC) |
Ownership (SVRA)
| Insider Ownership | +2.55% |
|---|---|
| Institutional Ownership | +106.87% |
| Shares Outstanding | 205.46M |
| Float | 129.75M |
| Short % of Float | +16.35% |
Source: Nexqual, October 29, 2026 at 21:53 UTC.
Leadership (SVRA)
Savara Inc. is led by Matthew Pauls, Chairman & CEO, per Nexqual as of October 29, 2026 at 21:53 UTC.
| Chairman & CEO | Matthew Pauls |
|---|---|
| COO & CFO | Robert Matthew Lutz |
| Executive Vice President of Global Medical Affairs | Brian Robinson |
| Executive Vice President of Global Technical Operations | Siddharth J. Advant |
Major Backers & Investors (SVRA)
Notable institutional backers of Savara Inc. include NEA Management Company, LLC, Bain Capital Life Sciences Investors, LLC, Venrock Adviser, LLC, according to Nexqual as of October 29, 2026 at 21:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| NEA Management Company, LLC | 11.91% |
| Bain Capital Life Sciences Investors, LLC | 8.57% |
| Venrock Adviser, LLC | 7.18% |
| Deerfield Management Company, L.P | 6.6% |
| TCG Crossover Management, LLC | 6.02% |
| Frazier Life Sciences Management, L.P. | 4.73% |
| Polar Capital Holdings PLC | 4.64% |
| Nantahala Capital Management, LLC | 3.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.08% |
| Vanguard Group | 3.86% |
Source: Nexqual, October 29, 2026 at 21:53 UTC.
From Savara Inc.'s Latest SEC 10-K Filing (filed 2026-03-13)
Key Strengths & Strategy (as disclosed to the SEC)
- Savara has exclusive access to the investigational, proprietary PARI eFlow® Nebulizer System for this indication along with a proprietary cell bank for the active drug substance of MOLBREEVI.
- MOLBREEVI is delivered via a proprietary eFlow® Nebulizer System (PARI Pharma GmbH, "PARI").
- PARI has five FDA-approved nebulizers based on the same eFlow® technology that is used in the proprietary device with MOLBREEVI.
- MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the investigational, proprietary eFlow® Nebulizer System (PARI Pharma GmbH).
Partnerships
- We have an exclusive license and a long-term supply agreement with PARI, as further discussed below, covering the eFlow® Nebulizer System for the administration of MOLBREEVI.
- In April 2019, we entered into a manufacture and supply agreement with GEMA, which was amended on December 7, 2022 and December 13, 2023 (the "GEMA Agreement"), pursuant to which GEMA may supply the active pharmaceutical ingredient ("API") for MOLBREEVI exclusively to us for commercial sale and continue to supply the API to us for clinical trials and research and development activities.
Legal & Regulatory Risks (Item 1A, quoted)
- We are substantially dependent upon the clinical, regulatory, and commercial success of our sole product candidate, MOLBREEVI. If we are unable to successfully complete clinical development of, obtain regulatory approval for, and successfully commercialize MOLBREEVI, our business may be harmed.
- Our MOLBREEVI product candidate may cause undesirable side effects or adverse events or have other properties that could delay or prevent our clinical development, regulatory approval, or commercialization.
- Our employees, independent contractors and consultants, principal investigators, CROs, CMOs, other vendors, and any future commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KOD | Kodiak Sciences Inc | USD 100.4 | ▲ 3.46% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 93.07 | ▲ 1.2% |
| ORKA | Oruka Therapeutics, Inc. | USD 96.65 | ▲ 0.71% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.39 | ▼ 1.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.45 | ▼ 0.04% |
| ABVX | Abivax SA | USD 89.06 | ▼ 0.87% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 21:53 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt